These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34771512)

  • 1. Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype.
    Ibragimova MK; Tsyganov MM; Litviakov NV
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
    Omarini C; Guaitoli G; Pipitone S; Moscetti L; Cortesi L; Cascinu S; Piacentini F
    Cancer Manag Res; 2018; 10():91-103. PubMed ID: 29391830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
    Zhukova LG
    Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
    Gregório AC; Lacerda M; Figueiredo P; Simões S; Dias S; Moreira JN
    Pathol Oncol Res; 2018 Oct; 24(4):701-716. PubMed ID: 28913723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Uhm JE; Park YH; Yi SY; Cho EY; Choi YL; Lee SJ; Park MJ; Lee SH; Jun HJ; Ahn JS; Kang WK; Park K; Im YH
    Int J Cancer; 2009 Mar; 124(6):1457-62. PubMed ID: 19065658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
    Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
    Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
    Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
    Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms.
    Yeh SJ; Hsu BJ; Chen BS
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
    Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
    BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.